Pasithea Q1 Net Loss $(2.87)M, EPS $(0.12); R&D up 70%

Pasithea Therapeutics Corp. reported a reduced net loss of $(2.87) million for Q1 2026, an improvement from $(3.56) million in Q1 2025, with basic and diluted loss per share improving to $(0.12) from $(1.61). This improvement occurred despite a 70% increase in research and development expenses to $2.94 million and higher net cash used in operating activities, which reached $(4.79) million. The company ended the quarter with $50.4 million in cash and cash equivalents and continues to advance its PAS-004 clinical trials, including completing initial cohorts for its advanced cancer study and initiating a Phase 1/1b trial for NF1 patients.